Skip to main navigation Skip to search Skip to main content

Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

  • Joseph G. Jurcic
  • , Farhad Ravandi
  • , John M. Pagel
  • , Jae H. Park
  • , B. Douglas Smith
  • , Moshe Yair Levy
  • , Elihu H. Estey
  • , Alexander E. Perl
  • , Hagop Kantarjian
  • , Dennis Earle
  • , Dragan Cicic
  • , David A. Scheinberg

    Research output: Contribution to journal › Article › peer-review

    Original languageAmerican English
    JournalBlood
    Volume126
    StatePublished - Dec 3 2015

    Disciplines

    • Medicine and Health Sciences
    • Immunology and Infectious Disease

    Cite this